# Halozyme Therapeutics, Inc. (HALO) stock price

URL: https://funkfolio.com/stock/HALO

> Halozyme Therapeutics, Inc. (HALO) trades at $95.97, is worth $10.94B, is priced at 24.0× earnings and scores 71/100. Valuation, financials and signals.

---

## Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics, Inc. (HALO) is a healthcare company (biotechnology) based in the United States. The share price is $95.97, down 0.55% on the day, which values the company at $10.94B. Price as of 17 Nov 2026, 21:39 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $95.97 −0.55% today
- **Market value:** $10.94B
- **P/E ratio:** 24.0× last 12 months
- **Forward P/E:** 9.1×
- **Funk Score:** 71/100
- **Against its own history:** Above its usual price usual price $83.15
- **200-week average:** $57.85 66% above
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 21:39 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Halozyme Therapeutics, Inc. in more detail

HALO trades at 24.0× its last twelve months' earnings, 9.1× next year's expected earnings, 6.1× sales. Measured against its own history, the price is 15% above what its usual multiples would imply ($83.15) — above its usual price. It sits 66% above its 200-week average of $57.85.

Over the last five fiscal years Halozyme Therapeutics, Inc. has compounded revenue 39.2% a year, earnings per share 23.0% a year, free cash flow 46.5% a year. Its Funk Score is 71 out of 100 (financial strength 6.2, profitability 7.6, growth 10.0, value 4.5, each out of 10).

In its favour: Altman Z in the safe zone; Share count keeps falling.

5 of the superinvestors tracked here hold HALO, including Josef Lakonishok (0.3% of the portfolio), John Overdeck and David Siegel (founders) (0.3% of the portfolio), Ray Dalio (founder) (0.1% of the portfolio).

### Superinvestors holding HALO

5 of the investors tracked here report a position in their latest 13F filing.

- [Josef Lakonishok LSV Asset Management](https://funkfolio.com/gurus/josef-lakonishok) 0.31% of portfolio · $166.4M · added · Q3 2026
- [John Overdeck and David Siegel (founders) Two Sigma Investments](https://funkfolio.com/gurus/two-sigma) 0.28% of portfolio · $388.5M · added · Q3 2026
- [Ray Dalio (founder) Bridgewater Associates](https://funkfolio.com/gurus/bridgewater) 0.15% of portfolio · $36.3M · trimmed · Q2 2026
- [Joel Greenblatt Gotham Asset Management](https://funkfolio.com/gurus/joel-greenblatt) 0.14% of portfolio · $57.9M · trimmed · Q2 2026
- [George Soros Soros Fund Management](https://funkfolio.com/gurus/george-soros) 0.11% of portfolio · $7.1M · new · Q3 2026

### Health Care companies of similar size

- [Penumbra PEN](https://funkfolio.com/stock/PEN)
- [Dr. Reddy's Laboratories RDY](https://funkfolio.com/stock/RDY)
- [Align Technology ALGN](https://funkfolio.com/stock/ALGN)
- [Cooper Companies COO](https://funkfolio.com/stock/COO)
- [Fresenius Medical Care FMS](https://funkfolio.com/stock/FMS)
- [Kymera Therapeutics KYMR](https://funkfolio.com/stock/KYMR)
- [DaVita DVA](https://funkfolio.com/stock/DVA)
- [Universal Health Services UHS](https://funkfolio.com/stock/UHS)
- [Repligen RGEN](https://funkfolio.com/stock/RGEN)
- [Bio-Techne TECH](https://funkfolio.com/stock/TECH)
- [BioMarin Pharmaceutical BMRN](https://funkfolio.com/stock/BMRN)
- [Avantor AVTR](https://funkfolio.com/stock/AVTR)

Side by side: [HALO vs DVA (Halozyme Therapeutics, Inc. vs DaVita)](https://funkfolio.com/compare/dva-vs-halo) [HALO vs UHS (Halozyme Therapeutics, Inc. vs Universal Health Services)](https://funkfolio.com/compare/halo-vs-uhs) [HALO vs KYMR (Halozyme Therapeutics, Inc. vs Kymera Therapeutics)](https://funkfolio.com/compare/halo-vs-kymr) [HALO vs RGEN (Halozyme Therapeutics, Inc. vs Repligen)](https://funkfolio.com/compare/halo-vs-rgen) [HALO vs FMS (Halozyme Therapeutics, Inc. vs Fresenius Medical Care)](https://funkfolio.com/compare/fms-vs-halo)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United States](https://funkfolio.com/companies/country/united-states) [All stocks A–Z](https://funkfolio.com/stocks)

### Halozyme Therapeutics, Inc. (HALO): questions and answers

**What is HALO's P/E ratio?**

Halozyme Therapeutics, Inc. trades at 24.0× its last twelve months' earnings and 9.1× next year's expected earnings. At its fiscal year-ends over the past 7 years the P/E ranged from 13.9× to 46.9×, with a median of 26.3×.

**What is Halozyme Therapeutics, Inc.'s market cap?**

Halozyme Therapeutics, Inc. is valued at $10.94B at a share price of $95.97.

**Is HALO overvalued or undervalued?**

Against its own history, HALO is above its usual price: the price is 15% above the $83.15 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is HALO above its 200-week moving average?**

Yes. HALO is 65.9% above its 200-week average of $57.85. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Halozyme Therapeutics, Inc. growing?**

Over the last five fiscal years Halozyme Therapeutics, Inc.'s revenue grew 39.2% a year and its earnings per share 23.0% a year; over ten years revenue grew 26.3% a year.

**Does HALO pay a dividend?**

Halozyme Therapeutics, Inc. does not currently pay a regular dividend.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Halozyme Therapeutics, Inc. (HALO) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/HALO

Underlying data: Yahoo Finance; company filings with the SEC.
